Equities

Beijing Konruns Pharmaceutical Co Ltd

603590:SHH

Beijing Konruns Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)20.66
  • Today's Change-0.13 / -0.63%
  • Shares traded707.70k
  • 1 Year change-42.71%
  • Beta1.3258
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments807614616
Total Receivables, Net337337257
Total Inventory483747
Prepaid expenses341725
Other current assets, total2.98122.97
Total current assets1,2301,017948
Property, plant & equipment, net417444435
Goodwill, net989898
Intangibles, net1,004932896
Long term investments984674696
Note receivable - long term------
Other long term assets--253283
Total assets3,7813,4253,371
LIABILITIES
Accounts payable834847
Accrued expenses322734
Notes payable/short-term debt9700
Current portion long-term debt/capital leases9.078.717.50
Other current liabilities, total1028867
Total current liabilities323172155
Total long term debt443.7111
Total debt1501219
Deferred income tax283045
Minority interest302264242
Other liabilities, total232930
Total liabilities721499483
SHAREHOLDERS EQUITY
Common stock160160160
Additional paid-in capital955992985
Retained earnings (accumulated deficit)2,0501,9311,876
Treasury stock - common(79)(125)(125)
Unrealized gain (loss)2720--
Other equity, total(53)(53)(8.11)
Total equity3,0602,9262,889
Total liabilities & shareholders' equity3,7813,4253,371
Total common shares outstanding159156156
Treasury shares - common primary issue1.023.513.51
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.